Skip to main content
OpenTrials
Completed

NCT Number: NCT03176225

Evaluate Safety and Effectiveness of XenoSure Biological Patch in the Application of Cardiac Repair

The purpose of this clinical trial is to collect safety and effectiveness data to support cardiac repair indication of XenoSure biologic patch. This trial is performed to meet the China FDA regulations for this kind of device. The clinical trial will be performed solely inside China under GCP regulation and all applicable China regulations on medical device clinical trial.

Completed

Looking for future studies?

Notify Me

Key information

Age range

Up to 6 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Chinese PLA General Hospital

Beijing, Beijing Municipality, 100853, China

About this study

The purpose of this clinical trial is to collect safety and effectiveness data to support cardiac repair indication of XenoSure biologic patch. This trial is performed to meet the China FDA regulations for this kind of device. The clinical trial will be performed solely inside China under GCP regulation and all applicable China regulations on medical device clinical trial.

There will be 144 subjects enrolled, including 72 subjects in the trial arm and 72 subjects in the control arm.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Man or woman aged below 6 years old
  • The expected lifetime of no less than 12 months
  • Patients with congenital heart disease in symptoms of ventricular septal defect, atrial septal defect and tetralogy of fallot who need the surgical repair.
  • Physical conditions and vital signs meet requirements for the surgery.
  • The subjects and/or their guardians sign the written Informed Consent Form.

Exclusion criteria

  • Patients with severe visceral diseases in liver, kidney, etc.
  • Patients have unstable vital signs and not suitable for the indications.
  • Patients with severe allergic history (especially allergic to bovine materials)
  • Patients with the past medical history of severe immunodeficiency disease
  • The subject has used or plans to use immunomodulatory drugs for more than half a year.
  • The subject with poor blood clotting function, which is defined as that pre-operative INR or APTT is prolonged over 30% than the reference value without drug intervention, or that blood platelet count is less than 100*10^9/L.
  • The subject has severe kidney disorders or diseases with the estimated glomerular filtration rate [GRF]<30mL/min/1.73m2.
  • The subject's ALT or AST level is 2.5 times higher than the upper normal limit or the subject has active liver disease or icterus.
  • The subject has participated in another clinical study within past 3 months or is participating in another clinical study now.
  • The investigator believes that the subject has other reasons unsuitable for inclusion.

Treatment and study plan

Open heart surgery to address the heart disease

Procedure

The patient will first have open heart surgery to achieve access to the diseased site in the heart

Close the defects with XenoSure Patch

Device

The heart defects, such as ASD (Atrial Septal Defect) or VSD (Ventricular Septal Defect ), are closed with LeMaitre XenoSure Patch.

Close the defects with Chest Polyester Patch

Device

The heart defects, such as ASD (Atrial Septal Defect) or VSD (Ventricular Septal Defect ), are closed with a Polyester Patch made by Shanghai Chest Medical Technology Co.

Primary outcomes

  1. Leakage rate at 6 month post-procedure measured by ultrasound

    Time frame: 6 months

    The heart defects should be totally closed by the patch. Any residual flow or leakage, measured by ultrasound, will be recorded. The percentage of the patients that show leakage post-procedure is the failure rate. The study is considered achieved its primary endpoint if the failure rate of the test device is non-inferior to the rate of the comparator device.

Sponsors and collaborators

Lead sponsor

LeMaitre Vascular

Industry

Registry information

Official study title

Random, Controlled, Single-blinded, Multi-center and Non-inferiority Clinical Study to Evaluate Safety and Effectiveness of XenoSure Biological Patch in the Application of Cardiac Repair

Important dates

Study start
2017
Primary completion
2020
Study completion
2024
First posted
Jun 5, 2017
Registry last updated
Mar 10, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.